Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?

[1]  S. Dimmeler,et al.  Endothelial Progenitor Cells: Characterization and Role in Vascular Biology , 2004, Circulation research.

[2]  Christoph Dehio,et al.  Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 , 2003, Nature Medicine.

[3]  L. Naldini,et al.  Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells , 2003, Nature Medicine.

[4]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[5]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[6]  P. Ratcliffe,et al.  Regulation of angiogenesis by hypoxia: role of the HIF system , 2003, Nature Medicine.

[7]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[8]  Christie M. Orschell,et al.  Peripheral Blood “Endothelial Progenitor Cells” Are Derived From Monocyte/Macrophages and Secrete Angiogenic Growth Factors , 2003, Circulation.

[9]  K. Sugimachi,et al.  Angiogenic switch as a molecular target of malignant tumors. , 2003, Journal of gastroenterology.

[10]  J. Haigh,et al.  Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. , 2003, The Journal of clinical investigation.

[11]  A. Luttun,et al.  Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? , 2003, The Journal of clinical investigation.

[12]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , 2003 .

[13]  J. Feige,et al.  Thrombospondins as anti-angiogenic therapeutic agents. , 2003, Current pharmaceutical design.

[14]  Kenneth J. Hillan,et al.  Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1 , 2003, Science.

[15]  T. H. van der Kwast,et al.  Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma , 2003, Journal of clinical pathology.

[16]  D. Ribatti,et al.  Analysis of the role of chemokines in angiogenesis. , 2003, Journal of immunological methods.

[17]  P. Carmeliet,et al.  A critical role of placental growth factor in the induction of inflammation and edema formation. , 2003, Blood.

[18]  R. Jain.  Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. , 2002, Seminars in oncology.

[19]  J. Folkman.  Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.

[20]  S. Rafii.  Vaccination against tumor neovascularization: Promise and reality. , 2002, Cancer cell.

[21]  D. Mukhopadhyay,et al.  KDR Stimulates Endothelial Cell Migration through Heterotrimeric G Protein Gq/11-mediated Activation of a Small GTPase RhoA* , 2002, The Journal of Biological Chemistry.

[22]  Lee Chao,et al.  Kallistatin is a new inhibitor of angiogenesis and tumor growth. , 2002, Blood.

[23]  W. Bellamy.  Vascular endothelial growth factor as a target opportunity in hematological malignancies , 2002, Current opinion in oncology.

[24]  A. D. de Vos,et al.  Vascular Endothelial Growth Factor–Induced Genes in Human Umbilical Vein Endothelial Cells: Relative Roles of KDR and Flt-1 Receptors , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[25]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Koichi Hattori,et al.  Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.

[27]  M. Teh,et al.  Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. , 2002, Experimental cell research.

[28]  Tobias Sjöblom,et al.  Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. , 2002, Cancer research.

[29]  Masanori Hangai,et al.  Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. , 2002, The American journal of pathology.

[30]  Napoleone Ferrara,et al.  VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.

[31]  R. Hynes.  A reevaluation of integrins as regulators of angiogenesis , 2002, Nature Medicine.

[32]  N. Voelkel,et al.  Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[33]  P. Richardson,et al.  The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment , 2002, Cancer research.

[34]  P. Campochiaro,et al.  Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. , 2002, Developmental cell.

[35]  F. Rickles,et al.  Tissue factor and angiogenesis in cancer , 2002, Current opinion in hematology.

[36]  G. Berchem,et al.  Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis , 2002, Oncogene.

[37]  M. Corada,et al.  A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. , 2002, Blood.

[38]  P. Campochiaro,et al.  Angiopoietin‐2 plays an important role in retinal angiogenesis , 2002, Journal of cellular physiology.

[39]  S. Donnini,et al.  Effect of hypoxia and endothelial loss on vascular smooth muscle cell responsiveness to VEGF-A: role of flt-1/VEGF-receptor-1. , 2002, Cardiovascular research.

[40]  S. Brodsky.  Coagulation, Fibrinolysis and Angiogenesis: New Insights from Knockout Mice , 2002, Nephron Experimental Nephrology.

[41]  Y. Ng,et al.  Tales of the cryptic: unveiling more angiogenesis inhibitors. , 2002, Trends in molecular medicine.

[42]  A. Sica,et al.  Tumor-associated macrophages: a molecular perspective. , 2002, International immunopharmacology.

[43]  G. Zambruno,et al.  Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. , 2002, Journal of cell science.

[44]  Till Acker,et al.  Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice , 2002, Nature Medicine.

[45]  Thomas N. Sato,et al.  Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF) , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[46]  A. D. de Vos,et al.  KDR (VEGF Receptor 2) Is the Major Mediator for the Hypotensive Effect of VEGF , 2002, Hypertension.

[47]  Lieve Moons,et al.  Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. , 2002, Journal of the American Society of Nephrology : JASN.

[48]  M. Shibuya,et al.  Tumor‐infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer , 2002, International journal of cancer.

[49]  H. DeLisser,et al.  Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration. , 2002, American journal of physiology. Cell physiology.

[50]  C. Jackson.  Matrix metalloproteinases and angiogenesis , 2002, Current opinion in nephrology and hypertension.

[51]  G. Yousef,et al.  Expanded Human Tissue Kallikrein Family – A Novel Panel of Cancer Biomarkers , 2002, Tumor Biology.

[52]  P. Carmeliet,et al.  Conditional switching of VEGF provides new insights into adult neovascularization and pro‐angiogenic therapy , 2002, The EMBO journal.

[53]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[54]  K. Acharya,et al.  Role of placenta growth factor in cardiovascular health. , 2002, Trends in cardiovascular medicine.

[55]  Peter Carmeliet,et al.  Molecular mechanisms of lymphangiogenesis in health and disease. , 2002, Cancer cell.

[56]  P. Carmeliet,et al.  Cell Type‐Specific Expression of Neuropilins in an MCA‐Occlusion Model in Mice Suggests a Potential Role in Post‐Ischemic Brain Remodeling , 2002, Journal of neuropathology and experimental neurology.

[57]  J. Isner,et al.  Endothelial progenitor cells for vascular regeneration. , 2002, Journal of hematotherapy & stem cell research.

[58]  N. Pavlakis,et al.  Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Rakesh K Jain,et al.  Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.

[60]  L. Devy,et al.  The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  David A. Cheresh,et al.  Role of integrins in cell invasion and migration , 2002, Nature Reviews Cancer.

[62]  A. Luttun,et al.  Vascular progenitors: from biology to treatment. , 2002, Trends in cardiovascular medicine.

[63]  T. Shiomi,et al.  Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF‐induced angiogenesis , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[64]  P. Ratcliffe,et al.  Oxygen sensors and angiogenesis. , 2002, Seminars in cell & developmental biology.

[65]  M. Trikha,et al.  Platelets and Cancer: Implications for Antiangiogenic Therapy , 2002, Seminars in thrombosis and hemostasis.

[66]  R. Strasser,et al.  Phenotypic overlap between hematopoietic cells with suggested angioblastic potential and vascular endothelial cells. , 2002, Journal of hematotherapy & stem cell research.

[67]  Ingeborg Stalmans,et al.  Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. , 2002, The Journal of clinical investigation.

[68]  R. K. Jain,et al.  Vessels of death or life. , 2001, Scientific American.

[69]  W. Welch,et al.  Monoclonal Antibodies to Vascular Endothelial Growth Factor (VEGF) And the VEGF Receptor, FLT-1, Inhibit the Growth of C6 Glioma in a Mouse Xenograft , 2001, Journal of Neuro-Oncology.

[70]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[71]  A. Eichmann,et al.  Endogenous origin of the lymphatics in the avian chorioallantoic membrane , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.

[72]  P. Bornstein,et al.  Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. , 2001, The American journal of pathology.

[73]  E. Weinberg,et al.  The role of vascular endothelial growth factor (VEGF) in vasculogenesis, angiogenesis, and hematopoiesis in zebrafish development , 2001, Mechanisms of Development.

[74]  Peter Bohlen,et al.  Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. , 2001, Cancer research.

[75]  K. Alitalo,et al.  Lymphatic Vessels as Targets of Tumor Therapy? , 2001, The Journal of experimental medicine.

[76]  S. Rafii,et al.  Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[77]  A. Ishida,et al.  Expression of vascular endothelial growth factor receptors in smooth muscle cells , 2001, Journal of cellular physiology.

[78]  P. Carmeliet,et al.  Clotting Factors Build Blood Vessels , 2001, Science.

[79]  D. Mukhopadhyay,et al.  Vascular Permeability Factor (VPF)/Vascular Endothelial Growth Factor (VEGF) Receptor-1 Down-modulates VPF/VEGF Receptor-2-mediated Endothelial Cell Proliferation, but Not Migration, through Phosphatidylinositol 3-Kinase-dependent Pathways* , 2001, The Journal of Biological Chemistry.

[80]  M. Mrksich,et al.  Direct Cell Adhesion to the Angiopoietins Mediated by Integrins* , 2001, The Journal of Biological Chemistry.

[81]  S. Kliche,et al.  VEGF Receptor Signaling and Endothelial Function , 2001, IUBMB life.

[82]  MS Pepper,et al.  Extracellular Proteolysis and Angiogenesis , 2001, Thrombosis and Haemostasis.

[83]  N. Ferrara.  Role of vascular endothelial growth factor in regulation of physiological angiogenesis. , 2001, American journal of physiology. Cell physiology.

[84]  S. Rafii,et al.  Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells , 2001, The Journal of experimental medicine.

[85]  Till Acker,et al.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions , 2001, Nature Medicine.

[86]  L. Devy,et al.  MT1‐MMP expression promotes tumor growth and angiogenesis through an up‐regulation of vascular endothelial growth factor expression , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[87]  P. Carmeliet,et al.  Heterogeneous vascular dependence of tumor cell populations. , 2001, The American journal of pathology.

[88]  J. Rakic,et al.  Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[89]  M. Karkkainen,et al.  Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. , 2001, Cancer research.

[90]  W. Schaffner,et al.  Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. , 2001, Cancer research.

[91]  M. Pepper,et al.  Lymphangiogenesis and tumor metastasis: myth or reality? , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[92]  D. Weng,et al.  Angiozyme: A Novel angiogenesis inhibitor , 2001, Current oncology reports.

[93]  Y. G. Kim,et al.  Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[94]  Nils Brünner,et al.  The Plasminogen Activator Inhibitor PAI-1 Controls In Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin: Implications for Antiangiogenic Strategies , 2001 .

[95]  L. Orci,et al.  Vascular endothelial growth factor‐C‐mediated lymphangiogenesis promotes tumour metastasis , 2001, The EMBO journal.

[96]  N. Ferrara,et al.  Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2) , 2001, The Journal of Biological Chemistry.

[97]  L. Ellis,et al.  The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. , 2001, Cancer research.

[98]  T. Noda,et al.  Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. , 2001, Cancer research.

[99]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[100]  M. Shoji,et al.  The Role of the Hemostatic System in Tumor Growth, Metastasis, and Angiogenesis: Tissue factor is a Bifunctional Molecule Capable of Inducing Both Fibrin Deposition and Angiogenesis in Cancer , 2001, International journal of hematology.

[101]  K. Shitara,et al.  and surface marker for the lineage of monocyte-macrophages in humans Flt-1 , vascular endothelial growth factor receptor 1 , is a novel cell , 2001 .

[102]  Steven A. Stacker,et al.  VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.

[103]  S. Stacker,et al.  Localization of vascular endothelial growth factor‐D in malignant melanoma suggests a role in tumour angiogenesis , 2001, The Journal of pathology.

[104]  M. Shibuya.  Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. , 2001, Cell structure and function.

[105]  R K Jain,et al.  Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[106]  S. Ekker,et al.  Distinct requirements for zebrafish angiogenesis revealed by a VEGF-A morphant. , 2000, Yeast.

[107]  P. Lacal,et al.  Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. , 2000, The Journal of investigative dermatology.

[108]  R K Jain,et al.  Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors. , 2000, Cancer research.

[109]  M Ancukiewicz,et al.  Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. , 2000, Cancer research.

[110]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[111]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[112]  P. Carmeliet,et al.  Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 , 2000, Mechanisms of Development.

[113]  A. Luttun,et al.  The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: Insights from genetic studies , 2000, Current atherosclerosis reports.

[114]  H. Blau,et al.  VEGF gene delivery to myocardium: deleterious effects of unregulated expression. , 2000, Circulation.

[115]  R. Jain,et al.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. , 2000, Cancer research.

[116]  N. Ferrara,et al.  A repressor sequence in the juxtamembrane domain of Flt‐1 (VEGFR‐1) constitutively inhibits vascular endothelial growth factor‐dependent phosphatidylinositol 3′‐kinase activation and endothelial cell migration , 2000, The EMBO journal.

[117]  G. Steiner,et al.  Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. , 2000, The Journal of urology.

[118]  J W Baish,et al.  Fractals and cancer. , 2000, Cancer research.

[119]  N. Rahimi,et al.  Receptor Chimeras Indicate That the Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1) Modulates Mitogenic Activity of VEGFR-2 in Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[120]  K. Shitara,et al.  Properties of Two VEGF Receptors, Flt‐1 and KDR, in Signal Transduction a , 2000, Annals of the New York Academy of Sciences.

[121]  S. Woo,et al.  Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[122]  K. Shitara,et al.  Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells , 2000, Oncogene.

[123]  J. Vaillant,et al.  Vegf, vegf‐B, vegf‐C and their receptors KDR, FLT‐1 and FLT‐4 during the neoplastic progression of human colonic mucosa , 2000, International journal of cancer.

[124]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[125]  N. Glazer,et al.  Angiopoietin-1 protects the adult vasculature against plasma leakage , 2000, Nature Medicine.

[126]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[127]  E. Wagner,et al.  Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. , 2000, Development.

[128]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[129]  R. Kerbel.  Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[130]  Thomas N. Sato,et al.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.

[131]  N. Fusenig,et al.  Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[132]  D. Hicklin,et al.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.

[133]  P. Carmeliet.  Developmental biology: Controlling the cellular brakes , 1999, Nature.

[134]  W. Gerald,et al.  Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts , 1999, Nature.

[135]  A. Luttun,et al.  Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure , 1999, Nature Medicine.

[136]  G. Oliver,et al.  Prox1 Function Is Required for the Development of the Murine Lymphatic System , 1999, Cell.

[137]  K. Plate,et al.  Expression and localization of placenta growth factor and PlGF receptors in human meningiomas , 1999, The Journal of pathology.

[138]  M. Corada,et al.  Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[139]  M. Skobe,et al.  Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. , 1999, The American journal of pathology.

[140]  A. Baici,et al.  Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases , 1999, FEBS letters.

[141]  P. Carmeliet,et al.  Targeted Deficiency or Cytosolic Truncation of the VE-cadherin Gene in Mice Impairs VEGF-Mediated Endothelial Survival and Angiogenesis , 1999, Cell.

[142]  P. Nawroth,et al.  Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[143]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[144]  Napoleone Ferrara,et al.  VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation , 1999, Nature Medicine.

[145]  Willem Flameng,et al.  Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 , 1999, Nature Medicine.

[146]  A. Hoffman,et al.  Mice that lack the angiogenesis inhibitor, thrombospondin 2, mount an altered foreign body reaction characterized by increased vascularity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[147]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[148]  Thomas N. Sato,et al.  Increased vascularization in mice overexpressing angiopoietin-1. , 1998, Science.

[149]  P. Krieg,et al.  VEGF mediates angioblast migration during development of the dorsal aorta in Xenopus. , 1998, Development.

[150]  R. Xavier,et al.  Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.

[151]  M. Shibuya,et al.  Neuropilin-1 Is a Placenta Growth Factor-2 Receptor* , 1998, The Journal of Biological Chemistry.

[152]  T. Noda,et al.  Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[153]  M. Skobe,et al.  Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization , 1998, Nature Medicine.

[154]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[155]  K. Alitalo,et al.  Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. , 1998, The American journal of pathology.

[156]  Jessica Lo,et al.  HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .

[157]  P. Opolon,et al.  Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[158]  E. Keshet,et al.  A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.

[159]  S. Bentolila,et al.  Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. , 1998, Blood.

[160]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[161]  S. Itohara,et al.  Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. , 1998, Cancer research.

[162]  Yihai Cao,et al.  Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-γ and migration of endothelial cells expressing Flt 1 , 1998, Oncogene.

[163]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[164]  P. V. van Diest,et al.  Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops , 1998, The Journal of pathology.

[165]  Y. Dor,et al.  Ischemia-driven angiogenesis. , 1997, Trends in cardiovascular medicine.

[166]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[167]  A. Harris,et al.  Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[168]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[169]  I. Takanami,et al.  Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. , 1997, Anticancer research.

[170]  H. Granger,et al.  Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[171]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[172]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[173]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[174]  W. Kaelin,et al.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[175]  A. Ullrich,et al.  Flk-1 as a target for tumor growth inhibition. , 1996, Cancer research.

[176]  A. Mantovani,et al.  Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.

[177]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[178]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[179]  M. Shibuya,et al.  Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[180]  L. Aiello,et al.  Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[181]  J. Rossant,et al.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.

[182]  M. Shibuya,et al.  A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. , 1995, Oncogene.

[183]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[184]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[185]  J. Winer,et al.  Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. , 1994, The Journal of biological chemistry.

[186]  T. Luther,et al.  Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. , 1994, The Journal of clinical investigation.

[187]  R K Jain,et al.  Barriers to drug delivery in solid tumors. , 1994, Scientific American.

[188]  D. Marmé,et al.  Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells , 1994, Journal of cellular biochemistry.

[189]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[190]  W. Hendrickson,et al.  A structural superfamily of growth factors containing a cystine knot motif , 1993, Cell.

[191]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[192]  G. Viglietto,et al.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[193]  M. Shibuya,et al.  Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. , 1990, Oncogene.

[194]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[195]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[196]  M. Knoth,et al.  Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. , 1968, Journal of the National Cancer Institute.

[197]  M. Greenblatt,et al.  Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. , 1968, Journal of the National Cancer Institute.

[198]  E. Goldmann.  The Growth of Malignant Disease in Man and the Lower Animals, with special reference to the Vascular System. , 1907, Proceedings of the Royal Society of Medicine.

[199]  M. Matsumura,et al.  Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. , 2003, Investigative ophthalmology & visual science.

[200]  Ingeborg Stalmans,et al.  VEGF: A modifier of the del22q11 (DiGeorge) syndrome? , 2003, Nature Medicine.

[201]  C. Betsholtz,et al.  Analysis of Mural Cell Recruitment to Tumor Vessels , 2002, Circulation.

[202]  M. Detmar,et al.  The α1β1 and α2β1 Integrins Provide Critical Support for Vascular Endothelial Growth Factor Signaling, Endothelial Cell Migration, and Tumor Angiogenesis , 2002 .

[203]  A. Luttun,et al.  Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.

[204]  D. Taverna,et al.  Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins , 2002, Nature Medicine.

[205]  Till Acker,et al.  Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration , 2001, Nature Genetics.

[206]  M. Shibuya,et al.  Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. , 2001, Human pathology.

[207]  Dian Feng,et al.  Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor , 2000, Laboratory Investigation.

[208]  V. Vincenti,et al.  Structure, expression and receptor-binding properties of placenta growth factor (PlGF). , 1999, Current topics in microbiology and immunology.

[209]  A. Ullrich,et al.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.

[210]  R. Bjercke,et al.  KDR activation is crucial for VEGF165-mediated Ca2+ mobilization in human umbilical vein endothelial cells. , 1999, The American journal of physiology.

[211]  M. Volm,et al.  Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. , 1997, Anticancer research.

[212]  N. Bouck,et al.  How tumors become angiogenic. , 1996, Advances in cancer research.